Last reviewed · How we verify
ONO-4685
At a glance
| Generic name | ONO-4685 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma (PHASE1)
- A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL (PHASE1)
- Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 (PHASE1)
- Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-4685 CI brief — competitive landscape report
- ONO-4685 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI